Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Psychedelic 5-MeO-DMT infused in healthy brains: first safety trial begins

NCT ID NCT07444788

First seen Mar 06, 2026 · Last updated Jun 23, 2026 · Updated 15 times

Summary

This early-stage study is testing how safe and tolerable intravenous 5-MeO-DMT is in 40 healthy adults aged 25-65. Participants receive either a low dose of the psychedelic or a placebo, and researchers monitor their heart rate, blood pressure, and subjective experiences. The goal is to understand the drug's effects and safety before any potential therapeutic use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 5-METHOXY-DIMETHYLTRYPTAMINE (5-MEO-DMT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Basel

    RECRUITING

    Basel, Canton of Basel-City, 4056, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

5-MeO-DMT (a psychedelic compound)

What this could lead to

If successful, this study could provide safety data to support future trials of 5-MeO-DMT for conditions like depression or anxiety.

What could go wrong

This is an early Phase 1 safety study in healthy people, not designed to test any disease treatment. The compound may cause intense psychological effects or side effects.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.